William Blair Issues Positive Estimate for ADPT Earnings

Key Points

• William Blair has increased their Q3 2025 earnings estimates for Adaptive Biotechnologies, projecting earnings per share of ($0.09), an improvement from their previous estimate of ($0.20).
• The company reported $49.94 million in revenue for their last quarter, surpassing analyst expectations, with a year-over-year revenue growth of 36.3%.
• Analysts have a consensus rating of “Moderate Buy” for Adaptive Biotechnologies, with a target price of $12.38, supported by several recent upgrades from various firms.

Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Free Report) - Equities researchers at William Blair upped their Q3 2025 earnings estimates for Adaptive Biotechnologies in a report issued on Monday, August 18th. William Blair analyst A. Brackmann now forecasts that the company will post earnings per share of ($0.09) for the quarter, up from their prior forecast of ($0.20). The consensus estimate for Adaptive Biotechnologies' current full-year earnings is ($0.92) per share. William Blair also issued estimates for Adaptive Biotechnologies' Q4 2025 earnings at ($0.10) EPS, FY2025 earnings at ($0.56) EPS, Q1 2026 earnings at ($0.19) EPS, Q2 2026 earnings at ($0.17) EPS, Q4 2026 earnings at ($0.15) EPS and FY2026 earnings at ($0.66) EPS.

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported ($0.17) EPS for the quarter, beating analysts' consensus estimates of ($0.24) by $0.07. Adaptive Biotechnologies had a negative net margin of 59.07% and a negative return on equity of 60.93%. The business had revenue of $49.94 million for the quarter, compared to analyst estimates of $49.40 million. During the same quarter last year, the business earned ($0.31) earnings per share. The business's revenue for the quarter was up 36.3% on a year-over-year basis.

ADPT has been the topic of a number of other research reports. Piper Sandler raised their price objective on shares of Adaptive Biotechnologies from $13.00 to $15.00 and gave the company an "overweight" rating in a research note on Wednesday, August 6th. Morgan Stanley raised their price objective on shares of Adaptive Biotechnologies from $7.00 to $9.00 and gave the company an "equal weight" rating in a research note on Monday, May 5th. Craig Hallum assumed coverage on shares of Adaptive Biotechnologies in a research note on Wednesday, June 18th. They set a "buy" rating and a $15.00 price objective on the stock. JPMorgan Chase & Co. raised their target price on shares of Adaptive Biotechnologies from $10.00 to $14.00 and gave the stock an "overweight" rating in a report on Wednesday, August 6th. Finally, TD Cowen raised their target price on shares of Adaptive Biotechnologies from $13.00 to $15.00 and gave the stock a "buy" rating in a report on Wednesday, August 6th. Seven research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, Adaptive Biotechnologies currently has a consensus rating of "Moderate Buy" and a consensus target price of $12.38.

Adaptive Biotechnologies Price Performance

NASDAQ ADPT opened at $12.30 on Thursday. Adaptive Biotechnologies has a 12 month low of $3.98 and a 12 month high of $13.37. The firm has a market capitalization of $1.87 billion, a PE ratio of -15.00 and a beta of 1.92. The company's 50 day simple moving average is $11.32 and its 200 day simple moving average is $9.35.

Hedge Funds Weigh In On Adaptive Biotechnologies

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Blair William & Co. IL acquired a new position in Adaptive Biotechnologies in the 1st quarter worth approximately $84,000. Personal CFO Solutions LLC acquired a new position in Adaptive Biotechnologies in the 1st quarter worth approximately $84,000. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Adaptive Biotechnologies in the 2nd quarter worth approximately $134,000. Wealth Enhancement Advisory Services LLC acquired a new position in Adaptive Biotechnologies in the 1st quarter worth approximately $87,000. Finally, Candriam S.C.A. acquired a new position in Adaptive Biotechnologies in the 1st quarter worth approximately $90,000. Institutional investors and hedge funds own 99.17% of the company's stock.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.